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The U.S. Food and Drug Administration Perspective*John C. Laschinger, MD, Nicole G. Ibrahim, PHD, Bram D. Zuckerman, MDT he U.S. Food and Drug Administration (FDA)is responsible for protecting and promotingthe public health of U.S. citizens. In keeping
with this mission, the FDA’s Center for Devices and
Radiological Health (CDRH) is tasked with ensuring
the safety, effectiveness, and quality of medical de-
vices; fostering innovation; and providing the public
with accurate scientiﬁc information about the prod-
ucts they oversee throughout the total product life
cycle. To help fulﬁll its mission, the CDRH has an
ongoing interest in promoting the quality and efﬁ-
ciency of clinical trials. Clinical trials that produce
high levels of valid scientiﬁc evidence to meet the reg-
ulatory approval threshold of reasonable assurance of
safety and effectiveness are dependent on excellent
trial design and execution. To this end, clearly deﬁned
clinical events and meaningful study outcome end-
points are essential elements for trials submitted for
regulatory review. Collaborative efforts among multi-
ple stakeholders to reach agreement on trial design el-
ements and standardized deﬁnitions for meaningful
clinical endpoints are especially important when un-
met medical needs call for the timely development
of safe and effective medical devices. The FDA sup-
ports these cooperative efforts as a tool to help
achieve shared goals of providing innovative medical
device solutions to critical public health challenges.
Prior multidisciplinary collaboration under the
umbrella of the Valve Academic Research Consortium*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Ofﬁce of Device Evaluation, Center for Devices and Radiological
Health, Food and Drug Administration, Silver Spring, Maryland. The
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.(VARC) produced consensus regarding standardized
deﬁnitions for adverse events and clinically mean-
ingful single and composite endpoints (VARC1 and
VARC 22) for device-, procedure-, and patient-related
safety and effectiveness measures for transcatheter
aortic valve replacement device trials. Following a
similar model, the Mitral Working Group of the Valve
Academic Research Consortium (MVARC) brought
together an international multidisciplinary group of
leading academic research organizations, physician-
scientists, regulators, and industry representatives to
provide recommendations for clinical study designs
and endpoint deﬁnitions for evaluating new trans-
catheter mitral valve replacement and repair devices.
The resulting 2-part document (1,2) provides an
important summary of the collective recommenda-
tions of MVARC, and from a regulatory perspective,
offers important suggestions on the design and end-
points of clinical trials intended to support pre-market
approval applications. Appropriate adoption of the
common deﬁnitional framework and trial design rec-
ommendations put forward in these documents will
help avoid future problems with trial design that can
adversely affect the ability to analyze data. Failure to
identify and classify appropriate study populations or
failure to deﬁne and use suitable individual or com-
posite endpoints that are adequate for providing
reasonable assurance of safety or effectiveness can be
obstacles to device approval. The MVARC documents
aim to address these issues proactively.SEE PAGES 278 AND 308Appropriate use of MVARC recommendations
regarding clinical trial design and deﬁnitions for sin-
gle and composite endpoints can facilitate the FDA’s
review of investigational device exemption sub-
missions to permit initiation of worthwhile clinical
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323trials in the United States. Further, uniform event
deﬁnitions and meaningful study endpoints can
improve the quality of pre-market approval sub-
missions to the FDA and enhance the efﬁciency of
data review and regulatory decision-making.
In contrast to aortic stenosis, the pathophysiology
of mitral regurgitation (MR) is complex and involves a
wide spectrum of valvular and ventricular pathol-
ogies. The design of medical devices aimed at treating
MR will have different characteristics and goals on
the basis of the underlying disease state. Importantly,
MVARC recognized the complexity of MR, and the
publication of their recommendations is particularly
useful during the early development stage of trans-
catheter mitral devices. Speciﬁcally, the MVARC
initiative coincides in timing with the early clinical
evaluation of several transcatheter mitral repair and
replacement devices in the United States and abroad.
The participation of U.S. sites in these crucial early
trials is an important result of 1 of CDRH’s strategic
priorities—promoting early feasibility studies in the
United States. The recommendations by MVARC will
be tested and may be reﬁned during these early
studies, and it is hoped that U.S. early feasibility
studies will facilitate an efﬁcient transition to future
pivotal clinical trials and, ultimately, earlier access
for U.S. patients to novel technologies. Harmonized
endpoint deﬁnitions incorporated into pre- and post-
market data collections utilizing national or interna-
tional registries can further increase the efﬁciency in
conducting clinical studies. Success in these areas
will help diminish the current time lag that exists in
the availability of some beneﬁcial medical devices in
the United States compared with other regions of the
world, an increasingly important concern among U.S.
patients and physicians.
We believe it is critical to utilize our regulatory au-
thority and understanding of the products we oversee
in establishing collaborative working relationships
with our partners in the federal government and
external constituencies to advance innovative ap-
proaches to beneﬁt public health. We continue to
encourage sponsors to contact the Agency early in
device development to facilitate efﬁcient, timely
initiation of clinical trials intended to support FDA
approval. Although a common set of deﬁnitions andendpoints is very helpful, speciﬁc trial design ele-
ments may depend on the particular device and pa-
tient population being studied. FDA approval to
initiate a clinical study of an investigational device
also depends on meeting the requirements for
nonclinical testing that are relevant to the anatomi-
cally and hemodynamically challenging mitral envi-
ronment. Therefore, it is extremely important that
sponsors understand the FDA’s nonclinical testing
expectations as early as possible to make efﬁcient use
of time and resources. High-quality study execution,
integrity, and validity are critically important for
clinical trials submitted to the FDA; efforts to ensure
adequate subject follow-up, minimize missing data,
limit bias, adjudicate events independently, and
the use of a pre-speciﬁed statistical analysis plan
(with adequate control of type I error) are important
considerations in our regulatory review. It is our
hope that publication of the MVARC document will
encourage sponsors and investigators to make use of
early interaction with the Agency. For this ﬁeld to
mature at an optimal pace in the United States, it is
essential that the FDA, sponsors, and investigators
continue to collaborate closely to develop high-
quality nonclinical and clinical data that ultimately
result in beneﬁcial devices for patients.
FDA also applauds the “global” approach adopted
by MVARC, in terms of both geography and expertise
(international representation of surgeons, interven-
tional cardiologists, clinical cardiologists, clinical
trialists, other allied specialists, and industry), which
we believe was instrumental to the success of this
effort. Such a process allowed for an open and
balanced discussion of complex issues. Finally, the
consensus report represents an important step in a
dynamic process, and the Agency looks forward to
continued involvement with MVARC as the tech-
nology and clinical application of transcatheter mitral
replacement and repair devices evolve.
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